The company develops therapeutics that target stroma-intrinsic mechanisms in the tumor microenvironment to combat drug resistance and immune evasion in cancer and autoimmune disorders. By disrupting the supportive role of stroma for cancer cells, their approach enhances understanding of cancer origins and improves patient outcomes.
Funding
$10K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer cells often develop resistance to drug therapies and evade immune system detection due to the supportive environment provided by the tumor microenvironment (TME). Current cancer treatments often fail to adequately address the stroma-intrinsic mechanisms within the TME that contribute to these challenges. This can lead to limited treatment efficacy and poor patient outcomes.
Solution
The company develops therapeutic interventions targeting the stroma, the non-cancerous cells and extracellular matrix within the tumor microenvironment. By modulating the stroma's supportive role, the company aims to disrupt drug resistance and enhance immune recognition of cancer cells. Their approach seeks to improve the efficacy of existing cancer therapies and develop novel treatments that address the underlying mechanisms of cancer progression and immune evasion. This strategy aims to provide a more comprehensive approach to cancer treatment by targeting both the tumor cells and their surrounding environment.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapies and improving patient outcomes in oncology and autoimmune disorders.
Features
- Development of therapeutics targeting specific components of the tumor stroma.
- Modulation of stromal cell signaling pathways to reduce drug resistance.
- Enhancement of immune cell infiltration and activity within the tumor microenvironment.
- Preclinical models to evaluate the efficacy of stroma-targeting therapies.